目的:探讨益心舒胶囊对2型糖尿病合并冠心病心绞痛患者的临床疗效。方法:选取2015年3月至2016年1月南阳市第一人民医院收治的2型糖尿病合并冠心病心绞痛患者88例,随机分为对照组与观察组,每组44例,对照组采用常规抗心绞痛及降糖药物治疗...目的:探讨益心舒胶囊对2型糖尿病合并冠心病心绞痛患者的临床疗效。方法:选取2015年3月至2016年1月南阳市第一人民医院收治的2型糖尿病合并冠心病心绞痛患者88例,随机分为对照组与观察组,每组44例,对照组采用常规抗心绞痛及降糖药物治疗,观察组在对照组的基础上加用益心舒胶囊治疗,2组患者均治疗8周。治疗后统计2组患者临床疗效;检测并比较治疗前后2组患者血糖、血脂水平及血小板活化指标水平的变化。结果:与对照组比较,治疗后观察组临床症状改善及心电图改善显效比例及有效率均显著升高,无效比例显著降低(P<0.05或P<0.01);与治疗前比较,治疗后2组患者FBG、2 h PBG、Hb A1c及TG、TC、LDL-C水平均明显降低,且观察组显著低于对照组(P<0.05或P<0.01),而2组患者HDL-C水平明显升高,且观察组显著高于对照组(P<0.01);治疗后对照组仅PAC-1及MAR较治疗前有明显降低(P<0.05),而观察组LAP、CD62P、PAC-1及MAR均较治疗前显著降低,且显著低于对照组(P<0.01)。结论:益心舒胶囊可显著改善2型糖尿病合并冠心病心绞痛患者的血糖、血脂水平,明显抑制血小板活化,提高临床疗效。展开更多
Objective：To study the distribution of gelsolin in human platelet and plasma,and the association with blood-stasis syndrome（BSS） of coronary heart disease（CHD）.Methods：Sixty patients with CHD（30 in BSS group an...Objective：To study the distribution of gelsolin in human platelet and plasma,and the association with blood-stasis syndrome（BSS） of coronary heart disease（CHD）.Methods：Sixty patients with CHD（30 in BSS group and 30 in non-BSS group） and 30 healthy subjects（control group） were included in this study.The classification of the syndrome was based on clinical symptoms and signs.Gelsolin concentration in platelet rich plasma（PRP）,platelet poor plasma（PPP）,filamentous actin（F-actin） and group-specific component globulin （Gc-globulin） of PPP were determined by enzyme-linked immunosorbent assay（ELISA）.The fluorescence intensity of CD62p and cytoplasmic calcium（[Ca^（2＋）]_i） in human platelets of patients and healthy persons was measured with flow cytometry.Results：Compared with the control group,gelsolin in PRP of the BSS group increased significantly（P0.01）,while that in PPP of the BSS and non-BSS groups decreased markedly（P0.05）, the CD62p,[Ca^（2＋）]_i of platelet,F-actin,and Gc-globulin of the BSS and non-BSS groups increased significantly （P0.01）.Compared with the non-BSS group,the gelsolin concentration in PRP of BSS group increased significantly（P0.01）,the[Ca^（2＋）]_i of platelet of the BSS group increased markedly（P0.01）,while the F-actin and Gc-globulin of the BSS group had no statistical defference（P0.05）.Conclusions：Gelsolin concentration in PRP was increased and accompanied by the elevated[Ca^（2＋）]_i of platelet in CHD with BSS,while gelsolin in PPP were lowered markedly.We speculate that plasma gelsolin may clear F-actin from circulation,thus resulting in depletion of plasma gelsolin significantly.This,in addition to the increased calcium influx of platelets,may lead to the gelsolin abnormal expression on platelets during the process of BSS in CHD.Therefore,platelet gelsolin may serve as a new potential biomarker and a therapeutic target of BSS in CHD.展开更多
Objective： To comparatively study the expressive conditions of platelet activation related factors （GPⅠb, GPⅡb-Ⅲa and GMP-140） in healthy subjects and patients with coronary heart disease （CHD） of blood-stasis...Objective： To comparatively study the expressive conditions of platelet activation related factors （GPⅠb, GPⅡb-Ⅲa and GMP-140） in healthy subjects and patients with coronary heart disease （CHD） of blood-stasis （BS） or non-blood-stasis （non-BS） syndrome, and to analyze the relationship between the activities of various glycoproteins and the polymorphism of genes. Methods： With case control design adopted, patients with the CHD （40 of BS, 37 of non-BS） and 39 healthy subjects for control, all fitting to the inclusion criteria, were selected in this study. The number of affected coronary branches was recorded by the contrast examination. The mean fluorescence intensity （MFI） of GPⅠb, GPⅡb-Ⅲa, and GMP-140 （CD42b, CD61, CD62p） in patients and healthy persons was measured with flow cytometry, the polymorphism of HPA-3 gene was detected by Taqman probe technique and that of HPA-2 gene was determined by gene sequencing. Results： MFI of CD61 and CD62p was higher in the CHD patients than in the healthy control, which was also higher in patients of BS syndrome than in patients of non-BS syndrome （P〈0.05）; MFI of CD42b was lower in the CHD patients than in the healthy control （P〈0.05）, but showing insignificant difference between BS and non-BS syndrome （P〉0.05）; at the same time, no significant difference of all the above-mentioned three MFI could be found in patients with various numbers of affected coronary branches, neither in patients with different genotypes at GPⅡb HPA-3 and GPⅠb HPA-2 polymorphism loci （P〉0.05）. Conclusion： （1） The activities of GP Ⅱ b-Ⅲa and GMP-140 were obviously increased in the genesis and developing process of CHD and CHD of BS syndrome, and so they could be taken as one of the objective indexes for microscopic diagnosis of BS syndrome. （2） The level of GPⅠb was lower in CHD patients than in healthy persons, but it was not a sensitive indicator for BS syndrome of CHD. （3） Levels of GP Ⅱb-Ⅲa, GPⅠb a展开更多
目的:探讨益心舒胶囊对2型糖尿病合并冠心病心绞痛患者的临床疗效。方法:选取河北省张家口市第一医院内分泌科收治的2型糖尿病合并冠心病心绞痛患者88例,随机分为对照组与观察组,每组44例。对照组给予常规降糖及抗心绞痛药治疗,观察组...目的:探讨益心舒胶囊对2型糖尿病合并冠心病心绞痛患者的临床疗效。方法:选取河北省张家口市第一医院内分泌科收治的2型糖尿病合并冠心病心绞痛患者88例,随机分为对照组与观察组,每组44例。对照组给予常规降糖及抗心绞痛药治疗,观察组在其基础上联合益心舒胶囊治疗,2组均治疗8周。治疗后统计2组临床疗效;检测并比较治疗前后2组患者血糖、血脂水平及血小板活化指标水平的变化。结果:与对照组比较,治疗后观察组临床症状改善及心电图改善显效比例及总有效率均显著升高,无效比例显著降低,差异有统计学意义(P<0.05或P<0.01);与治疗前比较,治疗后2组FBG、2 h PBG、HbA1c及TG、TC、LDL-C水平均明显降低,且观察组显著低于对照组,差异有统计学意义(P<0.05或P<0.01),而2组HDL-C水平明显升高,且观察组显著高于对照组(P<0.01);与治疗前比较,治疗后对照组仅PAC-1及MAR降低(P<0.05),而观察组LAP、CD62P、PAC-1及MAR降低,且明显低于对照组,差异有统计学意义(P<0.01)。结论:益心舒胶囊可显著改善2型糖尿病合并冠心病心绞痛患者的血糖、血脂水平,明显抑制血小板活化,提高临床疗效。展开更多
Over 400 researchers from 31 countries attended Carbon 2004, an international Carbon conference, held in Providence, Rhode Island, USA, from July 11-16, 2004. About 494 presentations (287 oral, 207 posters) at this co...Over 400 researchers from 31 countries attended Carbon 2004, an international Carbon conference, held in Providence, Rhode Island, USA, from July 11-16, 2004. About 494 presentations (287 oral, 207 posters) at this conference covered the following 13 areas: Adsorption and gas storage, Biological and medical application, Carbon nanomaterials, Chars/cokes and industrial applications, Electronic/Electrochemical properties and applications, Flame formed carbons, Materials characterization/techniques, Membranes/pyrocarbons and diamond films, Novel forms and chemically modified carbons, Porous carbons/activations, Precursor chemistry/carbonization and graphitization, Reactivity/catalysis and surface science, Structural carbons/fibers and composites. Carbon nanomaterials and nanostructure were highlighted at this conference, 12 of all 48 oral sessions and 112 of all 494 papers being on this topic. A pre-(conference) workshop, A Colloquium on Carbon Nanoforms, and three of the four plenary lectures reported the latest (development) and showed us the current trends in research on Carbon nanomaterials. At this conference, the idea was emphasized that the "nano" concept now not only represents some kinds of materials and structure, but also, much more important, brings us a new insight to carbon materials, novel or conventional. Carbon scientists firmly believe that they are trying to create the "golden age" of Carbon materials.Blood coagulation resistance of nonwoven single-walled carbon nanotubes and its implications for implantable prosthesesMENG Jie^1,SONG Li^2,KONG Hua^1,WANG Chao-ying^2,GUO Xiao-tian^1,XU Hai-yan^1,XIE Si-shen^2(1. Institute of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100005, China;2. Institute of Physics, Chinese Academy of Science, Beijing100080, China)Abstract:The anticoagulation property of a SWNT membrane is investigated in blood-contacting environments. The adsorption behaviors of fibrinogen, albumin and fresh plasma on SWNT membrane wer展开更多
文摘目的:探讨益心舒胶囊对2型糖尿病合并冠心病心绞痛患者的临床疗效。方法:选取2015年3月至2016年1月南阳市第一人民医院收治的2型糖尿病合并冠心病心绞痛患者88例,随机分为对照组与观察组,每组44例,对照组采用常规抗心绞痛及降糖药物治疗,观察组在对照组的基础上加用益心舒胶囊治疗,2组患者均治疗8周。治疗后统计2组患者临床疗效;检测并比较治疗前后2组患者血糖、血脂水平及血小板活化指标水平的变化。结果:与对照组比较,治疗后观察组临床症状改善及心电图改善显效比例及有效率均显著升高,无效比例显著降低(P<0.05或P<0.01);与治疗前比较,治疗后2组患者FBG、2 h PBG、Hb A1c及TG、TC、LDL-C水平均明显降低,且观察组显著低于对照组(P<0.05或P<0.01),而2组患者HDL-C水平明显升高,且观察组显著高于对照组(P<0.01);治疗后对照组仅PAC-1及MAR较治疗前有明显降低(P<0.05),而观察组LAP、CD62P、PAC-1及MAR均较治疗前显著降低,且显著低于对照组(P<0.01)。结论:益心舒胶囊可显著改善2型糖尿病合并冠心病心绞痛患者的血糖、血脂水平,明显抑制血小板活化,提高临床疗效。
基金the National Natural Science Foundation of China (No.81073086)
文摘Objective：To study the distribution of gelsolin in human platelet and plasma,and the association with blood-stasis syndrome（BSS） of coronary heart disease（CHD）.Methods：Sixty patients with CHD（30 in BSS group and 30 in non-BSS group） and 30 healthy subjects（control group） were included in this study.The classification of the syndrome was based on clinical symptoms and signs.Gelsolin concentration in platelet rich plasma（PRP）,platelet poor plasma（PPP）,filamentous actin（F-actin） and group-specific component globulin （Gc-globulin） of PPP were determined by enzyme-linked immunosorbent assay（ELISA）.The fluorescence intensity of CD62p and cytoplasmic calcium（[Ca^（2＋）]_i） in human platelets of patients and healthy persons was measured with flow cytometry.Results：Compared with the control group,gelsolin in PRP of the BSS group increased significantly（P0.01）,while that in PPP of the BSS and non-BSS groups decreased markedly（P0.05）, the CD62p,[Ca^（2＋）]_i of platelet,F-actin,and Gc-globulin of the BSS and non-BSS groups increased significantly （P0.01）.Compared with the non-BSS group,the gelsolin concentration in PRP of BSS group increased significantly（P0.01）,the[Ca^（2＋）]_i of platelet of the BSS group increased markedly（P0.01）,while the F-actin and Gc-globulin of the BSS group had no statistical defference（P0.05）.Conclusions：Gelsolin concentration in PRP was increased and accompanied by the elevated[Ca^（2＋）]_i of platelet in CHD with BSS,while gelsolin in PPP were lowered markedly.We speculate that plasma gelsolin may clear F-actin from circulation,thus resulting in depletion of plasma gelsolin significantly.This,in addition to the increased calcium influx of platelets,may lead to the gelsolin abnormal expression on platelets during the process of BSS in CHD.Therefore,platelet gelsolin may serve as a new potential biomarker and a therapeutic target of BSS in CHD.
基金Supported by the Major Program Project of National Natural Science Foundation of China(No.90409021)
文摘Objective： To comparatively study the expressive conditions of platelet activation related factors （GPⅠb, GPⅡb-Ⅲa and GMP-140） in healthy subjects and patients with coronary heart disease （CHD） of blood-stasis （BS） or non-blood-stasis （non-BS） syndrome, and to analyze the relationship between the activities of various glycoproteins and the polymorphism of genes. Methods： With case control design adopted, patients with the CHD （40 of BS, 37 of non-BS） and 39 healthy subjects for control, all fitting to the inclusion criteria, were selected in this study. The number of affected coronary branches was recorded by the contrast examination. The mean fluorescence intensity （MFI） of GPⅠb, GPⅡb-Ⅲa, and GMP-140 （CD42b, CD61, CD62p） in patients and healthy persons was measured with flow cytometry, the polymorphism of HPA-3 gene was detected by Taqman probe technique and that of HPA-2 gene was determined by gene sequencing. Results： MFI of CD61 and CD62p was higher in the CHD patients than in the healthy control, which was also higher in patients of BS syndrome than in patients of non-BS syndrome （P〈0.05）; MFI of CD42b was lower in the CHD patients than in the healthy control （P〈0.05）, but showing insignificant difference between BS and non-BS syndrome （P〉0.05）; at the same time, no significant difference of all the above-mentioned three MFI could be found in patients with various numbers of affected coronary branches, neither in patients with different genotypes at GPⅡb HPA-3 and GPⅠb HPA-2 polymorphism loci （P〉0.05）. Conclusion： （1） The activities of GP Ⅱ b-Ⅲa and GMP-140 were obviously increased in the genesis and developing process of CHD and CHD of BS syndrome, and so they could be taken as one of the objective indexes for microscopic diagnosis of BS syndrome. （2） The level of GPⅠb was lower in CHD patients than in healthy persons, but it was not a sensitive indicator for BS syndrome of CHD. （3） Levels of GP Ⅱb-Ⅲa, GPⅠb a
文摘目的:探讨益心舒胶囊对2型糖尿病合并冠心病心绞痛患者的临床疗效。方法:选取河北省张家口市第一医院内分泌科收治的2型糖尿病合并冠心病心绞痛患者88例,随机分为对照组与观察组,每组44例。对照组给予常规降糖及抗心绞痛药治疗,观察组在其基础上联合益心舒胶囊治疗,2组均治疗8周。治疗后统计2组临床疗效;检测并比较治疗前后2组患者血糖、血脂水平及血小板活化指标水平的变化。结果:与对照组比较,治疗后观察组临床症状改善及心电图改善显效比例及总有效率均显著升高,无效比例显著降低,差异有统计学意义(P<0.05或P<0.01);与治疗前比较,治疗后2组FBG、2 h PBG、HbA1c及TG、TC、LDL-C水平均明显降低,且观察组显著低于对照组,差异有统计学意义(P<0.05或P<0.01),而2组HDL-C水平明显升高,且观察组显著高于对照组(P<0.01);与治疗前比较,治疗后对照组仅PAC-1及MAR降低(P<0.05),而观察组LAP、CD62P、PAC-1及MAR降低,且明显低于对照组,差异有统计学意义(P<0.01)。结论:益心舒胶囊可显著改善2型糖尿病合并冠心病心绞痛患者的血糖、血脂水平,明显抑制血小板活化,提高临床疗效。
文摘Over 400 researchers from 31 countries attended Carbon 2004, an international Carbon conference, held in Providence, Rhode Island, USA, from July 11-16, 2004. About 494 presentations (287 oral, 207 posters) at this conference covered the following 13 areas: Adsorption and gas storage, Biological and medical application, Carbon nanomaterials, Chars/cokes and industrial applications, Electronic/Electrochemical properties and applications, Flame formed carbons, Materials characterization/techniques, Membranes/pyrocarbons and diamond films, Novel forms and chemically modified carbons, Porous carbons/activations, Precursor chemistry/carbonization and graphitization, Reactivity/catalysis and surface science, Structural carbons/fibers and composites. Carbon nanomaterials and nanostructure were highlighted at this conference, 12 of all 48 oral sessions and 112 of all 494 papers being on this topic. A pre-(conference) workshop, A Colloquium on Carbon Nanoforms, and three of the four plenary lectures reported the latest (development) and showed us the current trends in research on Carbon nanomaterials. At this conference, the idea was emphasized that the "nano" concept now not only represents some kinds of materials and structure, but also, much more important, brings us a new insight to carbon materials, novel or conventional. Carbon scientists firmly believe that they are trying to create the "golden age" of Carbon materials.Blood coagulation resistance of nonwoven single-walled carbon nanotubes and its implications for implantable prosthesesMENG Jie^1,SONG Li^2,KONG Hua^1,WANG Chao-ying^2,GUO Xiao-tian^1,XU Hai-yan^1,XIE Si-shen^2(1. Institute of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100005, China;2. Institute of Physics, Chinese Academy of Science, Beijing100080, China)Abstract:The anticoagulation property of a SWNT membrane is investigated in blood-contacting environments. The adsorption behaviors of fibrinogen, albumin and fresh plasma on SWNT membrane wer
